PPD Recognized for Excellence in Clinical Research Training
Brandon Hall Gold Awards honor innovation in employee learning and development
PPD was recognized with the Brandon Hall Gold Award in two categories – “best use of blended learning” for its clinical foundation program, which prepares clinical development employees for success in trial monitoring – and “best advance in learning measurement” for the company’s ability to measure learning effectiveness.
The clinical foundation program, one of PPD’s global employee-training courses, offers instructor-led sessions delivered through virtual customized classrooms, eLearning modules, and hands-on activities and scenarios. It offers an intensive study of clinical trial conduct, based on
PPD’s learning measurement model, applied to the company’s full range of employee training modules, is designed to enhance learning while reducing training hours and improving business performance to help fulfill PPD’s objective of fostering industry leading talent and culture.
“Our comprehensive employee learning and development programs empower our employees to perform at their peak, delivering our customers value and quality in their drug development programs,” said
Award entries were evaluated by a panel of veteran, independent senior industry experts,
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the